ChiCTR2000036657 版本V1.0 版本创建时间2020/09/18 22:10:45 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000036657 

最近更新日期:

Date of Last Refreshed on:

2020-08-24 20:05:29 

注册时间:

Date of Registration:

2020-08-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件。 基于驾驶表现评价II级色盲患者交通信号灯分辨能力的临床研究

Public title:

A clinical study on traffic signal discrimination of grade II parachromatoblepsia patients based on driving performance

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于驾驶表现评价II级色盲患者交通信号灯分辨能力的临床研究

Scientific title:

A clinical study on traffic signal discrimination of grade II parachromatoblepsia patients based on driving performance

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

朱晓宇 

研究负责人:

朱晓宇 

Applicant:

Xiaoyu Zhu 

Study leader:

Xiaoyu Zhu 

申请注册联系人电话:

Applicant telephone:

13795481676

研究负责人电话:

Study leader's telephone:

13795481676

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhuxiaoyu310@126.com

研究负责人电子邮件:

Study leader's E-mail:

zhuxiaoyu310@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市康定路380号

研究负责人通讯地址:

上海市康定路380号

Applicant address:

380 Kangding Road, Shanghai

Study leader's address:

380 Kangding Road, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市眼科医院

Applicant's institution:

Treatment Center/Shanghai Eye Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市眼科医院

Primary sponsor:

Treatment Center/Shanghai Eye Hospital

研究实施负责(组长)单位地址:

上海市康定路380号

Primary sponsor's address:

380 Kangding Road, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市眼科医院

具体地址:

康定路380号

Institution
hospital:

Treatment Center, Shanghai Eye Hospital

Address:

380 Kangding Road

经费或物资来源:

上海申康医院发展中心

Source(s) of funding:

Shanghai Shenkang Hospital Development Center

Target disease:

color anomalopia

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

拟探讨既往通过色盲检查图判定为II级色盲、无法申领驾驶证的人群,其驾驶小型汽车的可能性  

Objectives of Study:

To explore the possibility of driving small cars for people who have previously been judged as grade II color blind and unable to apply for driver's license by color blindness examination chart.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

18~60岁,被判定为II级色盲,可配合检查,双眼最佳矫正视力均≥0.8;签署知情同意书

Inclusion criteria

18-60 years old; was judged as grade II color blindness; can cooperate with the examination; the best corrected visual acuity of both eyes ≥ 0.8; signed informed consent

排除标准:

1)有任何一眼最佳矫正视力低于0.8,或有明显视野缺陷者;
2)有严重眼部疾病者,或眼部疾病可能影响色觉判断者;
3)有任何可能影响视觉质量高阶像差的眼部手术史者;
4)反应迟钝可能明显影响驾驶表现或辨别时间者;
5)除色觉外其他条件不符合驾驶证申领者;
6)除色觉外其他任何疾病可能影响驾驶表现和驾驶安全者。

Exclusion criteria:

1) The best corrected visual acuity (BCVA) of any eye was lower than 0.8 or had obvious visual field defect;

2) Patients with serious eye diseases or eye diseases may affect color perception judgment;

3) Any history of ocular surgery that may affect the visual quality of high-order aberrations;

4) Slow reaction may significantly affect driving performance or time discrimination;

5) Those who do not meet the requirements of driver's license except for color vision;

6) In addition to color vision, any other disease may affect driving performance and driving safety.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 1990-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 1990-01-01 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

静态交通信号灯图检查

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Static traffic light diagram inspection

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

动态交通信号灯图检查

Index test:

Dynamic traffic light diagram inspection

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

18~60岁,被判定为II级色盲,可配合检查,双眼最佳矫正视力均≥0.8。

例数:

Sample size:

40

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Aged 18-60 years; was judged as grade II color blindness; can cooperate with the examination; the best corrected visual acuity of both eyes >= 0.8

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市眼科医院 

单位级别:

三级 

Institution
hospital:

Treatment Center, Shanghai Eye Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

静态交通信号灯图检查

指标类型:

主要指标

Outcome:

Static traffic light diagram inspection

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动态交通信号灯图检查

指标类型:

次要指标

Outcome:

Dynamic traffic light diagram inspection

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Kappa

指标类型:

主要指标

Outcome:

Kappa

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Nonrandom

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan Clinical Trial Management Public Platform

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan Clinical Trial Management Public Platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF table

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-24 20:05:30